pfizer

Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What's ahead for the world's biggest drugmaker:

Keeping track of the latest product and food recalls can be a challenge, so Consumer Ally has collected them in one place for you to check each week. Here is this week's roundup of recalls: Some ready-to-eat salad products sold at major grocery chains, including Wegmans, Shop & Stop/Giant...

The largest pharmaceutical in the world announced its fourth recall of blockbuster cholesterol drug Lipitor due to reports of an "uncharacteristic odor."

According to the latest leaked U.S. diplomatic cables from WikiLeaks, Pfizer hired investigators to try to uncover evidence of corruption in order to pressure the Nigerian attorney general to drop the case against it.

Medical imaging and diagnostics powerhouse GE Healthcare teams up with pharmaceutical giant Johnson & Johnson to research methods of detecting Alzheimer's in patients -- even before they begin to exhibit symptoms of the devastating disease.

Wyeth Pharmecuticals on Wednesday lost its appeal of a decision that awarded $58 million in damages to three women who claimed the company's hormone-replacement drugs caused their breast cancer. The news could bode badly for the Pfizer-owned company, which has thousands of such cases pending.

With King in its fold, Pfizer -- which makes Lyrica and Celebrex -- believes it can build an industry-leading portfolio of pain relievers. Among King's most appealing entrants in that market is the new Embeda, designed to prevent misuse and abuse.

The world's top drug maker recalled 191,000 bottles of its anti-cholesterol drug Lipitor due to reports of a moldy odor emanating from bottles supplied by a third-party – the same problem that resulted in the recall of millions of Tylenol bottles. Pfizer spokesman Rick Chambers said the...

After a fairly quiet Monday, the crunch of quarterly reports resumes Tuesday, with reports expected from Coach, MasterCard, Molson Coors and Pfizer. Here's what to watch.

Teva Pharmaceutical Industries said Tuesday that the U.S. Food and Drug Administration approved its generic version of Pfizer's antidepressant Effexor XR, or Venlafaxine.